The EHDN Imaging Working Group has now produced its third newsletter. The newsletter provides relevant updates on imaging studies, research advancements, and innovative techniques in neuroimaging. Imaging Working Group (iWG) NEWSLETTER Edition 4 | October 2025 […]
Kategoria: Uncategorized
EHDN Newsletter – 56th edition
The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]
EHDN Platform Meeting in collaboration with HDYO and EHA – UniQure topline results: unpacking the outcome so far
The Platform Meeting will take place on Tuesday, 18th of November, at 17:00-18:30 CET. The presentations by Prof. Anne Rosser and Prof. Sarah Tabrizi will be followed by an expert panel discussion. The event will be chaired by Prof. Åsa Petersén. All are very welcome to attend and follow this highly anticipated conversation. We […]
Positive Topline Results for AMT-130
On 24 September, uniQure announced exciting topline results for their Phase 1/2 study of AMT-130 in HD. The high dose of AMT-130 met the study’s primary endpoint by demonstrating statistically significant slowing of disease progression (as assessed by the composite Unified Huntington’s Disease Rating Scale) at 36 months compared to a propensity score-matched external control […]
Enroll-HD periodic dataset – PDS7
The seventh release of the Enroll-HD periodic dataset, PDS7, has been fully curated and is now available. PDS7 contains data from 30,511 Enroll-HD study participants encompassing 112,992 study visits, making it one of the largest cohort datasets available to researchers. Read more here. […]
EHDN LESLEY JONES SEED FUND PROGRAM
The program is currently open and receiving applications! Head here for more information and the application form Deadline: 1st November 2025 23:59 CET […]
next steps for Pridopidine
On 25 July, Prilenia shared that the application for pridopidine had been rejected for marketing authorisation in HD by the European Medicines Agency’s Committee for Medicinal Products for Human Use. The application was based on post-hoc analyses from the EHDN-endorsed, Phase 3 PROOF-HD study, suggesting that the orally administered sigma-1 receptor agonist may offer potential […]
EHDN Imaging Working Group (iWG) newsletter – edition 3
The EHDN Imaging Working Group has now produced its third newsletter. The newsletter provides relevant updates on imaging studies, research advancements, and innovative techniques in neuroimaging. Imaging Working Group (iWG) NEWSLETTER Edition 3 | July 2025 […]
EHDN Newsletter – 55th edition
The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]
EHDN Imaging Working Group (iWG) newsletter – edition 2
The EHDN Imaging Working Group is now producing a regular newsletter. The newsletter provides relevant updates on imaging studies, research advancements, and innovative techniques in neuroimaging. Welcome to the inaugural edition of the Imaging Working Group (iWG) NEWSLETTER Edition 2 | March 2025 […]